Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We investigated the effect of rituximab on systemic bone metabolism in patients with seropositive rheumatoid arthritis (RA). Methods: Twenty seropositive patients with RA were enrolled and administered one cycle of rituximab. If RA became active for > 6 months after the first rituximab cycle, a second cycle was initiated; otherwise, no additional treatment was administered. Patients were divided into two groups according to the number of rituximab treatment cycles. Results: In patients treated with a second cycle, the total hip bone mineral density (BMD) was clinically low, whereas the serum levels of receptor activator of nuclear factor kappa-B ligand (RANKL) were increased at 12 months. BMD in patients treated with one cycle did not change at 12 months, whereas serum RANKL levels decreased at all time points. DAS28 activity improved in both groups from baseline to 4 months; however, from 4 to 12 months, DAS28 activity worsened in the develgroup with the second cycle but remained stable in the group with one cycle. Conclusions: Systemic inflammation, reflected by increased disease activity, may be responsible for the increase in RANKL levels, which causes systemic bone loss in rituximab-treated patients with RA. Although rituximab affects inflammation, it does not seem to alter systemic bone metabolism in RA.
Abstract
Background/Aims: We investigated the effect of rituximab on systemic bone metabolism in patients with seropositive rheumatoid arthritis (RA). Methods: Twenty seropositive patients with RA were enrolled and administered one cycle of rituximab. If RA became active for > 6 months after the first rituximab cycle, a second cycle was initiated; otherwise, no additional treatment was administered. Patients were divided into two groups according to the number of rituximab treatment cycles. Results: In patients treated with a second cycle, the total hip bone mineral density (BMD) was clinically low, whereas the serum levels of receptor activator of nuclear factor kappa-B ligand (RANKL) were increased at 12 months. BMD in patients treated with one cycle did not change at 12 months, whereas serum RANKL levels decreased at all time points. DAS28 activity improved in both groups from baseline to 4 months; however, from 4 to 12 months, DAS28 activity worsened in the develgroup with the second cycle but remained stable in the group with one cycle. Conclusions: Systemic inflammation, reflected by increased disease activity, may be responsible for the increase in RANKL levels, which causes systemic bone loss in rituximab-treated patients with RA. Although rituximab affects inflammation, it does not seem to alter systemic bone metabolism in RA.
참고문헌 (33)
- Wheater G, "Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis", Osteoporos Int, 22, pp.3067~3072 (2011)
- Edwards JC, "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis", N Engl J Med, 350, pp.2572~2581 (2004)
- Manabe N, "Connection between B lymphocyte and osteoclast differentiation pathways", J Immunol, 167, pp.2625~2631 (2001)
- Kelly C, "Peripheral bone density in patients with rheumatoid arthritis and factors which influence it", Eur J Intern Med, 13, pp.423~ (2002)
- Kim SY, "Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis", Arthritis Res Ther, 12, pp.R154~ (2010)
- Xue AL, "Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis", Medicine(Baltimore), 96, pp.e6983~ (2017)
- Tak PP, "Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial", Ann Rheum Dis, 70, pp.39~46 (2011)
- Keystone E, "Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies", Ann Rheum Dis, 68, pp.216~221 (2009)
- Hein G, "Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis : a prospective open-label pilot study", Rheumatol Int, 31, pp.269~272 (2011)
- Wheater G, "Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study", PLoS One, 13, pp.e0201527~ (2018)
- Li Y, "B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo", Blood, 109, pp.3839~3848 (2007)
- Hayer S, "B-cell infiltrates induce endosteal bone formation in inflammatory arthritis", J Bone Miner Res, 23, pp.1650~1660 (2008)
- Boyce BF, "Bruton and Tec : new links in osteoimmunology", Cell Metab, 7, pp.283~285 (2008)
- Aletaha D, "2010 Rheumatoid arthritis classification criteria : an American College of Rheumatology", European League Against Rheumatism collaborative initiative, 2010, pp.62, 2569~2581
- Lee SY, "Obesity potentially protects against systemic bone loss in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors", Clin Exp Rheumatol, 39, pp.125~131 (2021)
- Landewé R, "Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate : results from the trial of etanercept and methotrexate with radiographic and patient outcomes", Arthritis Rheum, 54, pp.3119~3125 (2006)
- Kanamaru F, "Expression of membrane-bound and soluble receptor activator of NF-kappaB ligand(RANKL)in human T cells", Immunol Lett, 94, pp.239~246 (2004)
- Nakashima T, "Osteoclasts and the immune system", J Bone Miner Metab, 27, pp.519~229 (2009)
- Thurlings RM, "Synovial tissue response to rituximab : mechanism of action and identification of biomarkers of response", Ann Rheum Dis, 67, pp.917~925 (2008)
- Nakou M, "Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis : depletion of memory B cells correlates with clinical response", Arthritis Res Ther, 11, pp.R131~ (2009)
- Leandro MJ, "Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy", Rheumatology(Oxford), 46, pp.29~36 (2007)
- Meednu N, "Production of RANKL by memory B cells : a link between B cells and bone erosion in rheumatoid arthritis", Arthritis Rheumatol, 68, pp.805~816 (2016)
- Rana AK, "Monocytes in rheumatoid arthritis : circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis", Int Immunopharmacol, 65, pp.348~359 (2018)
- Boumans MJ, "Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis", Ann Rheum Dis, 71, pp.108~113 (2012)
- Fardellone P, "Bone loss, osteoporosis, and fractures in patients with rheumatoid arthritis : a review", J Clin Med, 9, pp.3361~ (2020)
- Cauley JA, "Health ABC Study. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study", J Bone Miner Res, 22, pp.1088~1095 (2007)
- Redlich K, "Inflammatory bone loss : pathogenesis and therapeutic intervention", Nat Rev Drug Discov, 11, pp.234~250 (2012)
- Polzer K, "Interleukin-1 is essential for systemic inflammatory bone loss", Ann Rheum Dis, 69, pp.284~290 (2010)
- Kleyer A, "Arthritis and bone loss : a hen and egg story", Curr Opin Rheumatol, 26, pp.80~84 (2014)
- Rosenthall L, "Range of change of measured BMD in the femoral neck and total hip with rotation in women", J Bone Miner Metab, 22, pp.496~499 (2004)
- Sugiguchi S, "Preferential reduction of bone mineral density at the femur reflects impairment of physical activity in patients with low-activity rheumatoid arthritis", Mod Rheumatol, 20, pp.69~73 (2010)
- Wang Y, "Effects of glucocorticoids on osteoporosis in rheumatoid arthritis : a systematic review and meta-analysis", Osteoporos Int, 31, pp.1401~1409 (2020)
- Nakamura M, "A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer(ESPRESSO-01)", Oncologist, 22, pp.592~600 (2017)